MTNB · Matinas Biopharma Holdings Inc
United States · RS rating 74 · As of 2026-11-03
| Price | 1.14 USD |
|---|---|
| 1-day change | -11.6% |
| RS rating (overall / 1M / 3M / 12M) | 74 / 3 / 98 / 38 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 37 / 53 / 41 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +30.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +62.1% |
| Market cap (USD) | $4.0M |